Skip to main content

Ohio State University to Offer Vermillion's SELDI-Based Homebrew TTP Dx

NEW YORK (GenomeWeb News) - Ohio State University will make available a SELDI-based hematology test made by Vermillion, the company said today.
Vermillion, formerly known as Ciphergen, said OSU will license the homebrew test for managing patients with the blood-clotting disorder thrombotic thrombocytopenic purpura. The test was co-developed with the school’s University Research Foundation.
The laboratory-developed test uses SELDI mass spectrometry to measure enzyme levels for “precise, quantitative and reproducible results” for TTP. OSU plans to make it available by the end of the month through its reference laboratory.
Financial terms of the agreement were not released.
TTP is a potentially lethal disorder caused by an enzymatic deficiency that causes platelet clumping and loss of red blood cells, which in turn can lead to neurological and nephrological abnormalities.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.